Under the GSAV law, real-world evidence become important for health technology assessment (HTA) procedures under the AMNOG law.
This symposium focuses on post-launch data collection as well as registry studies and examines the requirements from the viewpoint of HTA bodies G-BA and IQWiG and of statutory health insurance GKV.
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.